Browse GLS2

Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion
Domain PF12796 Ankyrin repeats (3 copies)
PF04960 Glutaminase
Function

Plays an important role in the regulation of glutamine catabolism. Promotes mitochondrial respiration and increases ATP generation in cells by catalyzing the synthesis of glutamate and alpha-ketoglutarate. Increases cellular anti-oxidant function via NADH and glutathione production. May play a role in preventing tumor proliferation.

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006536 glutamate metabolic process
GO:0006537 glutamate biosynthetic process
GO:0006541 glutamine metabolic process
GO:0006543 glutamine catabolic process
GO:0006626 protein targeting to mitochondrion
GO:0006820 anion transport
GO:0006835 dicarboxylic acid transport
GO:0006839 mitochondrial transport
GO:0008652 cellular amino acid biosynthetic process
GO:0009063 cellular amino acid catabolic process
GO:0009064 glutamine family amino acid metabolic process
GO:0009065 glutamine family amino acid catabolic process
GO:0009084 glutamine family amino acid biosynthetic process
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0014047 glutamate secretion
GO:0015711 organic anion transport
GO:0016053 organic acid biosynthetic process
GO:0016054 organic acid catabolic process
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0043648 dicarboxylic acid metabolic process
GO:0043650 dicarboxylic acid biosynthetic process
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0046942 carboxylic acid transport
GO:0051222 positive regulation of protein transport
GO:0070585 protein localization to mitochondrion
GO:0072593 reactive oxygen species metabolic process
GO:0072655 establishment of protein localization to mitochondrion
GO:0090316 positive regulation of intracellular protein transport
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901606 alpha-amino acid catabolic process
GO:1901607 alpha-amino acid biosynthetic process
GO:1903214 regulation of protein targeting to mitochondrion
GO:1903533 regulation of protein targeting
GO:1903747 regulation of establishment of protein localization to mitochondrion
GO:1903749 positive regulation of establishment of protein localization to mitochondrion
GO:1903829 positive regulation of cellular protein localization
GO:1903955 positive regulation of protein targeting to mitochondrion
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0004359 glutaminase activity
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa04724 Glutamatergic synapse
hsa04727 GABAergic synapse
hsa04964 Proximal tubule bicarbonate reclamation
hsa00250 Alanine, aspartate and glutamate metabolism
hsa00471 D-Glutamine and D-glutamate metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-70614: Amino acid synthesis and interconversion (transamination)
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-210500: Glutamate Neurotransmitter Release Cycle
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-112316: Neuronal System
R-HSA-112310: Neurotransmitter Release Cycle
R-HSA-5628897: TP53 Regulates Metabolic Genes
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-112315: Transmission across Chemical Synapses
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GLS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GLS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GLS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3820.335
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1390.83
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7730.178
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4350.121
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3670.863
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.520.843
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0090.985
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5290.456
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6880.395
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-2.1720.0317
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-2.3410.0719
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1770.401
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GLS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GLS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GLS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GLS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GLS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GLS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GLS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGLS2
Nameglutaminase 2 (liver, mitochondrial)
Aliases LGA; hLGA; breast cell glutaminase; glutaminase I; phosphate-activated glutaminase; phosphate-dependent glut ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GLS2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GLS2.
ID Name Drug Type Targets #Targets
DB00142Glutamic AcidSmall MoleculeAADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, CPQ, DNPEP ......69